Problems in patient management and the impact of osteoporosis therapy on the incidence of clinical infection
The global diversion of health resources during the COVID-19 pandemic from the provision of routine medical care, and the more frequent and severe course of this infection in older patients justify the need to study the impact of the pandemic on the management of patients with osteoporosis.Aim – to...
Saved in:
Main Authors: | O. M. Lesnyak, E. N. Gladkova, K. E. Zotkina, A. L. Grigoryeva, Yu. A. Safonova, O. Yu. Kuznetsova, M. A. Pokhaznikova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2021-07-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/3036 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01) -
Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
by: O. V. Dobrovolskaya, et al.
Published: (2019-05-01) -
Treatment of patients with osteoporosis: issues of therapy duration, adherence, and replacement
by: N. V. Toroptsova
Published: (2018-12-01) -
Experience with denosumab therapy for osteoporosis in rheumatoid arthritis patients receiving glucocorticoids
by: I. S. Dydykina, et al.
Published: (2018-06-01) -
Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
by: N. V. Toroptsova, et al.
Published: (2016-01-01)